National Center for Advancing Translational Sciences; Notice of Closed Meeting, 65992 [2019-25985]
Download as PDF
<![CDATA[
65992
Federal Register / Vol. 84, No. 231 / Monday, December 2, 2019 / Notices
jbell on DSKJLSW7X2PROD with NOTICES
The NAEPPCC also fulfills charges,
similar to those above, set forth in the
Children’s Health Act of 2000 (Pub. L.
106–310). In addition, the Children’s
Health Act of 2000 tasks the NHLBI,
through the NAEPPCC, with submitting
recommendations to Congress on ways
to strengthen and improve coordination
of asthma-related activities of the
federal government.
The NAEPPCC consists of
representatives from the major
scientific, professional, governmental,
and voluntary organizations interested
in asthma. The Committee’s primary
mission is to advise the NHLBI on
matters concerning asthma and to
facilitate the exchange of information on
asthma activities among the member
agencies and voluntary health
organizations.
The NHLBI administers and
coordinates the Coordinating
Committee. The Coordinating
Committee meetings are open to the
public and include presentations and
discussion on a variety of topics
concerning asthma, including activities
and projects of the Committee.
NHLBI Asthma Guidelines
NHLBI produced its first asthma
clinical practice guidelines in 1991 and
an update was issued in 2007,
Guidelines for the Diagnosis and
Management of Asthma (EPR–3). In
2011, the National Asthma Education
and Prevention Program concluded
another update was needed and an
Advisory Council of the NHLBI
determined in 2012 that a needs
assessment should be conducted prior
to engaging in any guideline activity. In
2014, NHLBI Council convened an
Asthma Expert Panel Working Group to
conduct a needs assessment. The
Working Group recommended that an
update should be made to the 2007
clinical practice guidelines; identified
five priority topics for immediate
systematic review and update
(subsequently changed to six priority
topics); and recommended that the
NHLBI maintain the NAEPP structure,
coordinate the systematic reviews, and
update the report. After public
comments on the draft needs assessment
report were received and reviewed, the
Working Group recommended adding a
sixth priority topic to the report.
The six priority topic areas identified
by the Working Group are: (1)
Adjustable medication dosing in
recurrent wheezing and asthma
(‘‘intermittent therapy’’), (2) long acting
anti-muscarinic agents in asthma
management as add-on to inhaled
corticosteroids, (3) bronchial
thermoplasty in adult severe asthma, (4)
VerDate Sep<11>2014
17:10 Nov 29, 2019
Jkt 250001
fractional exhaled nitric oxide (FeNO)
in diagnosis, medication selection, and
monitoring treatment response, (5)
remediation of indoor allergens (house
dust mites/pets), and (6) the role of
immunotherapy in the treatment of
asthma.
The Working Group also
recommended that several emerging
topic areas be acknowledged and
monitored, but did not yet merit
systematic review.
NAEPPCC Expert Panel Report 4 (EPR–
4) Working Group
The NAEPPCC Expert Panel Working
Group 4 (EPR–4) was established in
2018 to update selected topics in the
2007 Guidelines for the Diagnosis and
Management of Asthma, Expert Panel
Report 3 (EPR–3). The Expert Panel
Working Group members used findings
from the following NHLBI-supported
systematic reviews to develop updates
to the 2007 guidelines.
• Role of Immunotherapy in the
Treatment of Asthma
• Intermittent Inhaled Corticosteroids
and Long-Acting Muscarinic Antagonist
for Asthma
• Effectiveness of Indoor Allergen
Reduction in Management of Asthma
• Effectiveness and Safety of
Bronchial Thermoplasty in Management
of Asthma
• The Clinical Utility of Fractional
Exhaled Nitric Oxide (FeNO) in Asthma
Management
The Expert Panel Working Group
members include asthma content
experts, specialists and primary care
clinicians, health policy experts,
implementation and dissemination
experts and individuals with experience
using the GRADE (Grading of
Recommendations Assessment,
Development and Evaluation) approach.
A methodologist provided technical
support to the Working Group.
This RFI should not be construed as
a solicitation for applications or
proposals, or as an obligation in any
way on the part of the United States
Federal government. The Federal
government will not pay for the
preparation of any information
submitted or for the government’s use.
Additionally, the government cannot
guarantee the confidentiality of the
information provided.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Center for Advancing
Translational Sciences; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Center for
Advancing Translational Sciences Special
Emphasis Panel—SBIR.
Date: December 18, 2019.
Time: 1:00 p.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, One
Democracy Plaza, 6701 Democracy
Boulevard, Bethesda, MD 20892 (Telephone
Conference Call).
Contact Person: Jing Chen, Ph.D., Scientific
Review Officer, Office of Scientific Review,
National Center for Advancing Translational
Sciences (NCATS), National Institutes of
Health, 6701 Democracy Blvd., Democracy 1,
Room 1080, Bethesda, MD 20892–4874,
chenjing@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.859, Pharmacology,
Physiology, and Biological Chemistry
Research; 93.350, B—Cooperative
Agreements; 93.859, Biomedical Research
and Research Training, National Institutes of
Health, HHS)
Dated: November 25, 2019.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2019–25985 Filed 11–29–19; 8:45 am]
BILLING CODE 4140–01–P
Dated: October 30, 2019.
James P. Kiley,
Director, Division of Lung Diseases, NHLBI.
[FR Doc. 2019–26017 Filed 11–29–19; 8:45 am]
BILLING CODE 4140–01–P
PO 00000
Frm 00028
Fmt 4703
Sfmt 9990
E:\FR\FM\02DEN1.SGM
02DEN1
]]>Agencies
[Federal Register Volume 84, Number 231 (Monday, December 2, 2019)]
[Notices]
[Page 65992]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-25985]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Center for Advancing Translational Sciences; Notice of
Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Center for Advancing Translational
Sciences Special Emphasis Panel--SBIR.
Date: December 18, 2019.
Time: 1:00 p.m. to 2:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, One Democracy Plaza, 6701
Democracy Boulevard, Bethesda, MD 20892 (Telephone Conference Call).
Contact Person: Jing Chen, Ph.D., Scientific Review Officer,
Office of Scientific Review, National Center for Advancing
Translational Sciences (NCATS), National Institutes of Health, 6701
Democracy Blvd., Democracy 1, Room 1080, Bethesda, MD 20892-4874,
[email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.859,
Pharmacology, Physiology, and Biological Chemistry Research; 93.350,
B--Cooperative Agreements; 93.859, Biomedical Research and Research
Training, National Institutes of Health, HHS)
Dated: November 25, 2019.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2019-25985 Filed 11-29-19; 8:45 am]
BILLING CODE 4140-01-P
